SEMI-SYNTHESIS AND EVALUATION OF HESPERETIN DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS7

2018 ◽  
Vol 8 (4) ◽  
pp. 7-12
Author(s):  
Huan Tran The ◽  
Dao Tran Thanh

Background: Inhibition of acetylcholinesterase are regarded as one of promising approach to treat Alzheimer’s disease. Hesperetin is a potential flavonoid for further development in this direction. Objectives: Semi-synthesized and assayed for hesperetin derivatives’s acetylcholinesterase inhibitory activity in vitro. Materials and methods: Ester and ether derivatives of hesperetin were semi-synthesized. The semi-synthesis compounds were tested for acetylcholinesterase inhibitory activity in vitro according to the Ellman’s method. Results: Hesperetin is obtained by hydrolysing hesperidin. Then, two ester and two ether derivatives were semi-synthesized from hesperetin. The results showed that some of the semi-synthesis hesperetin derivatives displayed stronger acetylcholinesterase inhibitory activity than hesperetin. Among them, derivative 1 has the best activity with an IC50 value of 43.50 μM. Conclusions: Four hesperetin derivatives were semi-synthesized and investigated their acetylcholinesterase inhibitory activity, some of which showed improvement in activity. Key words: Hesperetin, semi-synthesis, inhibit, enzyme, acetylcholinesterase

MedPharmRes ◽  
2017 ◽  
Vol 1 (1) ◽  
pp. 15-25
Author(s):  
Dao Tran ◽  
Son Tran ◽  
Vi Nguyen ◽  
Tri Le ◽  
Minh Thai ◽  
...  

In this study, a total of twenty chalcones were synthesized via Claisen-Schmidt condensation reaction and evaluated for their in vitro acetylcholinesterase inhibitory activities using Ellman’s method. Molecular docking studies on acetylcholinesterase were performed to elucidate the interactions between these chalcone derivatives and acetylcholinesterase active site at the molecular level. From the series, six compounds (S1-5 and S17) exhibited strong acetylcholinesterase inhibitory activities with IC50 values below 100 µM compared to the parent unsubstituted chalcone. Compound S17 (4’-amino-2-chlorochalcone) showed the strongest acetylcholinesterase inhibitory activity in the investigated group with IC50 value of 36.10 µM. Molecular modeling studies were consistent with the results of in vitro acetylcholinesterase inhibitory activities, and chalcone S17 could be considered as a potential lead compound for the development of new acetylcholinesterase inhibitors.


2020 ◽  
Vol 17 (9) ◽  
pp. 1155-1163
Author(s):  
Lintao Yu ◽  
Jian Shi ◽  
Xinfeng Cheng ◽  
Keren Wang ◽  
Shuang Liu ◽  
...  

Background: Due to the complex etiology of AD, multi-target-directed ligands (MTDLs), combining two or more distinct pharmacological moieties, have been developed in both symptomatic and disease-modifying efficiencies and are considered as an effective way for the treatment of AD. Methods: To test their biological activities, including AChE/BChE inhibitory activity and MAOA/ MAO-B inhibitory activity. In addition, molecular modeling studies were performed to afford insight into the binding mode. Results: The results displayed that compound 4c showed the best AChE inhibitory activity with an IC50 value of 4.2 μM, which was supported by the kinetic study and docking study. Compound 4c was also a selective MAO-B inhibitor (IC50 = 8.2 μM). Moreover, compound 4c could cross the blood-brain barrier in vitro. Conclusion: Compound 4c deserved to further study as a potential multifunctional agent for the treatment of Alzheimer’s disease.


Molecules ◽  
2019 ◽  
Vol 24 (13) ◽  
pp. 2392 ◽  
Author(s):  
Derya Osmaniye ◽  
Begüm Nurpelin Sağlık ◽  
Ulviye Acar Çevik ◽  
Serkan Levent ◽  
Betül Kaya Çavuşoğlu ◽  
...  

Alzheimer’s disease (AD) is the most common of the degenerative brain diseases and is described together with the impairment of cognitive function. Patients with AD lose the capability to code new memories, and life conditions are extremely difficult. The development of new drugs in this area continues at a great pace. A novel series of thiazole-piperazine hybrids, aimed against Alzheimer’s disease (AD), have been synthesized. The structure identification of synthesized compounds was elucidated by 1HNMR, 13C-NMR, and LCMSMS spectroscopic methods. The inhibitory potential of the synthesized compounds on cholinesterase enzymes was investigated. The compounds 3a, 3c and 3i showed significant inhibitory activity on the acetylcholinesterase (AChE) enzyme. On the other hand, none of the compounds showed significant inhibitory activity on the butyrylcholinesterase (BChE) enzyme. In addition to enzyme inhibition studies, enzyme kinetic studies were performed to observe the effects of the most active inhibitor compounds on the substrate–enzyme relationship. In addition to in vitro tests, docking studies also indicated that compound 3c potentially acts as a dual binding site AChE inhibitor.


2013 ◽  
Vol 8 (3) ◽  
pp. 1934578X1300800
Author(s):  
Buket Bozkurt Sarikaya ◽  
Strahil Berkov ◽  
Jaume Bastida ◽  
Gulen Irem Kaya ◽  
Mustafa Ali Onur ◽  
...  

A GC-MS analysis of alkaloids in the aerial parts and bulbs of Galanthus x valentinei nothosubsp. subplicatus was performed for the first time. Totally, twenty-six alkaloids were identified, of which tazettine and galanthindole were the major ones. Acetylcholinesterase inhibitory activity of the alkaloidal extracts was determined using modified in vitro Ellman's method. Significant anticholinesterase activity was observed in the tested samples (bulbs: IC50 = 21.3 μg/mL, aerial parts: IC50 = 16.3 μg/mL).


2020 ◽  
Vol 19 ◽  
Author(s):  
Maja Przybyłowska ◽  
Krystyna Dzierzbicka ◽  
Szymon Kowalski ◽  
Klaudia Chmielewska ◽  
Iwona Inkielewicz-Stepniak

: The aim of this work is review of tacrine analogues from the last three years, which were not included in the latest review work, donepezil and galantamine hybrids from 2015 and rivastigmine derivatives from 2014. In this account we summarize the efforts toward the development and characterization of non-toxic inhibitors of cholinesterases based on mentioned drugs with various interesting additional properties such as antioxidant, decreasing β-amyloid plaque aggregation, nitric oxide production, pro-inflammatory cytokines release, monoamine oxidase-B activity, cytotoxicity and oxidative stress in vitro and in animal model that classify these hybrids as potential multifunctional therapeutic agents for Alzheimer’s disease. Moreover, herein, we have described the cholinergic hypothesis, mechanisms of neurodegeneration and current pharmacotherapy of Alzheimer’s disease which is based on the restoration of cholinergic function through blocking enzymes that break down acetylcholine.


2021 ◽  
Vol 13 (26) ◽  
pp. 45-49
Author(s):  
Fernanda Granja da Silva Oliveira ◽  
Bruno de Oliveira Veras ◽  
Juliane Maria Dos Santos Silva ◽  
Deyzi Caroline da Silva Barbosa ◽  
Tayane de Cássia Dias Mendes Silva ◽  
...  

2021 ◽  
Vol 28 ◽  
Author(s):  
Agnieszka Jankowska ◽  
Grzegorz Satała ◽  
Gniewomir Latacz ◽  
Anna Partyka ◽  
Annamaria Lubelska ◽  
...  

Background: There is currently no drug that slows the process of neurodegeneration or alleviates the cognitive and depressive symptoms in patients with Alzheimer’s disease. Due to the increasing number of Alzheimer’s patients, there is an urgent need to develop novel drugs with neuroprotective, procognitive, and antidepressant properties. Objective: The aim of this study was to design, synthesize, and evaluate novel aminoalkanamides with serotonin 5-HT1A/5-HT7 receptor affinity and phosphodiesterase (PDE) inhibitory activity as a new approach to combat neurodegeneration and symptoms of Alzheimer’s disease. Methods: The newly designed compounds were synthesized using classical methods of organic chemistry and tested in vitro for their receptor affinity, functional profile, enzyme inhibition, and ADME properties. The neuroprotective effect against H2O2-induced increase of reactive oxygen species level was tested in SH-SY5Y cells. The novel object recognition and forced swimming tests were used to evaluate the procognitive and antidepressant activity, respectively. Results: Synthesized aminoalkanamides were characterized as potent 5-HT1A receptor antagonists with additional 5-HT7 receptor antagonistic properties and PDE4B inhibitory activity. Selected compound 15 showed neuroprotective, procognitive, and antidepressant properties. In addition, compound 15 revealed suitable ADME properties expressed as a good membrane permeability and a high metabolic stability. Conclusion: This study revealed a new class of compounds that may be useful in the search for an effective drug in the alleviation of neurodegeneration and symptoms of Alzheimer’s disease.


Author(s):  
Dang Kim Thu ◽  
Hoang Thu Thuy ◽  
Bui Thi Thanh Duyen ◽  
Luc Thi Thanh Hang ◽  
Nguyen Thi Trang ◽  
...  

Medicinal plants are a potential source of enzyme acetylcholinesrerase (AChE) inhibitors, a key target in the treatment of Alzheimer’s disease. This paper studies the AChE inhibitory activity and the antioxidant effect of Persea Americana Mill extract. The sample leave, seed, exocarp and mesocarp of avocado were extracted with 50% ethanol and subsequently fractionated with n-hexane, ethyl acetate (EtOA) and n-butanol (n-BuOH) solvents. The AChE inhibitory activity was evaluated by Ellman’s colorimetric method and the antioxidant activity by screening DPPH free radicals.  The results show that the seed of Persea Americana extract had the strongest AChE inhibitory activity and antioxidant effect, followed by the leave extract, and the exocarp extract and mesocarp extract were the weakest. The Persea Americana seed extract inhibited AChE activity in a dose-dependent manner with an IC50 value of 47.43 ± 0.5 μg/mL and the antioxidant effect with an IC50 value of 68.7 ± 0.35 µg/mL. The results also show that n–BuOH fraction of Persea Americana seed extract had strong AChE inhibitory and antioxidant activities with an IC50 value of 15.24 ± 0.52 µg/ml and 15.73 ± 0.42 μg/mL, respectively. The study results suggest that the Persea Americana Mill is a promising ingredient in Alzheimer’s disease prevention and treatment. Keywords Persea Americana Mill, Acetylcholinesrerase inhibitors (AChE), Alzheimer, DPPH. References [1] M.M. Essa et al., Neuroprotective effect of natural products against Alzheimer's disease, Neurochem Res. 37(9) (2012) 1829.[2] B. McGleenon, K. Dynan, A. Passmore,. Acetylcholinesterase inhibitors in Alzheimer's disease, British journal of clinical pharmacology. 48 (1999) 471.[3] P. B. Watkins et al, Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease, In: Jama. pp. 992 (1994).[4] O. Adeyemi, S. Okpo, O. Ogunti,. Analgesic and anti-inflammatory effects of the aqueous extract of leaves of Persea americana Mill (Lauraceae). In: Fitoterapia. pp. 375 (2002).[5] P.D.D. Dzeufiet, et al, Antihypertensive potential of the aqueous extract which combine leaf of Persea americana Mill. (Lauraceae), stems and leaf of Cymbopogon citratus (DC) Stapf.(Poaceae), fruits of Citrus medical L.(Rutaceae) as well as honey in ethanol and sucrose experimental model. In: BMC complementary and alternative medicine. p. 507 (2014).[6] B.I. Brai, A. Odetola, P. Agomo,. Hypoglycemic and hypocholesterolemic potential of Persea americana leaf extracts, Journal of medicinal food. 10(2) (2007) 356.[7] Phạm Khuê. Bệnh Alzheimer. Nhà xuất bản Y học (2002).[8] Đàm Trung Bảo. Các gốc tự do, Tạp chí Dược học. 6 (2001) 29 [9] F.R. Mowsumi, A. Rahaman, N.C. Sarker, B.K. Choudhury, S. Hossain, In vitro relative free radical scavenging effects of Calocybe indica (milky oyster) and Pleurotus djamor (pink oyster), World J Pharm Pharm Sci. 4(07) (2015) 186.[10] Y. Bao, Y. Qu, J. Li, Y. Li, X. Ren, K. Maffuci, et al. In vitro and in vivo antioxidant activities of the flowers and leaves from Paeonia rockii and identification of their antioxidant constituents by UHPLC-ESI-HRMSn via pre-column DPPH reaction, Molecules. 23(2) (2018) 392.[11] Phan Kế Sơn. Đánh giá tác dụng ức chế enzym Acetylcholinsterase in vitro của các phân đoạn dịch chiết Hoàng Liên Ô rô (Mahonia Nepalensis DC., họ Berberidaceae). Khóa luận tốt nghiệp Đại học ngành Dược học. Khoa Y Dược - Đại học Quốc Gia Hà Nội (2017).[12] D. Mohammad, P. Chan, J. Bradley, K. Lanctôt, N. Herrmann, Acetylcholinesterase inhibitors for treating dementia symptoms-a safety evaluation, Expert opinion on drug safety. 16(9) (2017) 1009.[13] A. Mohammadi-Farani, S.S. Darbandi, A. Aliabadi, Synthesis and acetylcholinesterase inhibitory evaluation of 4-(1, 3-dioxoisoindolin-2-yl)-N-phenyl benzamide derivatives as potential anti-alzheimer agents, Iranian journal of pharmaceutical research. IJPR 15(3) (2016) 313.[14] T.B. Fernandes, M.R. Cunha, R.P. Sakata, T.M. Candido, A.R. Baby, M.T. Tavares, et al. Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease, Archiv der Pharmazie. 350(11) (2017) 1700163.[15] M.I. Alkhalf, W.S. Alansari, E.A. Ibrahim, M.E. Elhalwagy, Anti-oxidant, anti-inflammatory and anti-cancer activities of avocado (Persea americana) fruit and seed extract. Journal of King Saud University-Science (2018).[16] F. Gómez, S. Sánchez, M. Iradi, N. Azman, M. Almajano, Avocado seeds: extraction optimization and possible use as antioxidant in food, Antioxidants. 3(2) (2014) 439.[17] O.A. Folasade, R.A. Olaide, T.A. Olufemi, Antioxidant properties of Persea americana M. seed as affected by different extraction solvent, Journal of Advances in Food Science & Technology. 3(2) (2016) 101.[18] C.A. Alagbaoso, I.I. Tokunbo, O.S. Osakwe, Comparative study of antioxidant activity and mineral composition of methanol extract of seeds of ripe and unripe avocado pear (Persea americana, Mill.). NISEB Journal. 15(4) (2017).[19] G. Oboh, V.O. Odubanjo, F. Bello, A.O. Ademosun, S.I. Oyeleye, E.E. Nwanna et al. Aqueous extracts of avocado pear (Persea americana Mill.) leaves and seeds exhibit anti-cholinesterases and antioxidant activities in vitro, Journal of basic and clinical physiology and pharmacology. 27(2) (2016) 131.[20] H. Cavdar, M. Senturk, M. Guney , S. Durdagi, G. Kayik, C.T. Supuran, et al. Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies, Journal of enzyme inhibition and medicinal chemistry. 34(1) (2019) 429.    


Sign in / Sign up

Export Citation Format

Share Document